Genfit to Participate in H.C. Wainwright Investment Conference

GENFIT, a biopharmaceutical company based in Lille, France, and Cambridge, Massachusetts, will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The event, scheduled to begin at 11:00 AM Eastern Time, will take place in New York City.

The company, dedicated to improving the lives of patients with rare and life-threatening liver diseases, will present at the conference, offering an update on its ongoing research and development efforts. GENFIT focuses on treating Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). The firm also targets other serious diseases, including cholangiocarcinoma (CCA), urea cycle disorders (UCD), and organic acidemia (OA).

GENFIT’s portfolio of therapeutic assets includes Iqirvo® (elafibranor), which was acceleratedly approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). The drug is now marketed in several countries.

Additionally, GENFIT has a diagnostic franchise, including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). The company, which is BCorp™ certified, has been active in developing high-potential molecules from early to advanced pre-commercialization stages.